- Home
- Companies
- Myeloid Therapeutics
- Products
- mRNA Cell Therapy Technology
mRNA Cell Therapy Technology
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through a rapid, single-day cell process. This method provides significant advantages to the patient, contract development, and manufacturing organizations (CDMO) over allogeneic approaches.
Empowering
Empowering myeloid cells to produce anti-tumor agents and modify the tumor microenvironment.
Harnessing
Harnessing the frequent migration of myeloid cells from the blood into solid tumors and sites of inflammation.
Directing
Directing phagocytic properties of myeloid cells, including the capability to recognize and engulf cancer cells.
Bridging
Bridging innate and adaptive immunity to elicit a broad anti-tumor immune response with tumor-specific T cells.